Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 4/20 | 1.00 |
| ▸ | JAK1 | P23458 | 12/20 | 0.84 |
| ▸ | JAK2 | O60674 | 8/20 | 0.74 |
| ▸ | JAK3 | P52333 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2242762 | 0.91 | JAK1 (1.00) | TYK2JAK1JAK2JAK3 | |
| SCHEMBL2235228 | 0.90 | JAK2 (0.82) | TYK2JAK1JAK2JAK3 | |
| SCHEMBL2235843 | 0.89 | TYK2 (0.81) | TYK2JAK1JAK2JAK3 | |
| SCHEMBL2237545 | 0.87 | JAK1 (0.79) | TYK2JAK1JAK2JAK3 | |
| SCHEMBL7971660 | 0.86 | JAK2 (0.80) | TYK2JAK1JAK2JAK3 | |
| SCHEMBL2239713 | 0.86 | JAK2 (0.82) | TYK2JAK1JAK2JAK3 | |
| SCHEMBL2237596 | 0.85 | JAK2 (1.00) | TYK2JAK1JAK2JAK3 | |
| SCHEMBL29464036 | 0.85 | JAK2 (1.00) | TYK2JAK1JAK2JAK3 | |
| SCHEMBL2186752 | 0.85 | JAK1 (0.76) | TYK2JAK1JAK2JAK3 | |
| SCHEMBL2239758 | 0.85 | JAK1 (0.80) | TYK2JAK1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10206907-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2019-02-19 | — | — | US | claimed |
| US-9415037-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2016-08-16 | — | — | US | claimed |
| US-20150150856-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2015-06-04 | — | — | US | claimed |
| US-8853240-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2014-10-07 | — | — | US | claimed |
| EP-2361251-B1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-04-30 | — | — | EP | claimed |
| US-11203595-B2 | Aza-indazole compounds for use in tendon and/or ligament injuries | NOVARTIS AG (CH) | 2021-12-21 | — | — | US | disclosed |
| US-20210188842-A1 | AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | NOVARTIS AG (CH) | 2021-06-24 | — | — | US | disclosed |
| US-10766894-B2 | Aza-indazole compounds for use in tendon and/or ligament injuries | NOVARTIS AG (CH) | 2020-09-08 | — | — | US | disclosed |
| US-20190300522-A1 | AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2019-10-03 | — | — | US | disclosed |
| US-10206907-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2019-02-19 | — | — | US | disclosed |
| US-10206907-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2019-02-19 | — | — | US | disclosed |
| US-20170035738-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2017-02-09 | — | — | US | disclosed |
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2011-08-04 | — | — | US | disclosed |
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2011-08-04 | — | — | US | disclosed |
| US-20100291151-A1 | 1-METHYLPYRAZOLE MODULATORS OF SUBSTANCE P, CALCITONIN GENE-RELATED PEPTIDE, ADRENERGIC RECEPTOR, AND/OR 5-HT RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100029709-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029709-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029709-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010010191-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES. | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010010190-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150856-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TLR6, TRAF6, BMP6 | TYK2 191/4885JAK1 100/4885JAK2 242/4885 |
| US-20100291151-A1 | 1-METHYLPYRAZOLE MODULATORS OF SUBSTANCE P, CALCITONIN GENE-RELATED PEPTIDE, ADRENERGIC RECEPTOR, AND/OR 5-HT RECEPTOR | TACR1, HTR3A, HTR3C | TYK2 4791/4885JAK1 2767/4885JAK2 2588/4885 |
| US-10766894-B2 | Aza-indazole compounds for use in tendon and/or ligament injuries | MMP1, TIMP3, ALPI | TYK2 2892/4885JAK1 956/4885JAK2 1504/4885 |
| US-10206907-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | TRAF6, TLR6, IL6 | TYK2 234/4885JAK1 115/4885JAK2 222/4885 |
| US-20170035738-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TLR6, TRAF6, BMP6 | TYK2 191/4885JAK1 100/4885JAK2 242/4885 |
| US-20100029709-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TRAF6, IL6, TLR6 | TYK2 127/4885JAK1 83/4885JAK2 154/4885 |
| US-20190300522-A1 | AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | MMP1, TIMP3, ALPI | TYK2 2892/4885JAK1 956/4885JAK2 1504/4885 |
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TRAF6, IL6, TLR6 | TYK2 171/4885JAK1 84/4885JAK2 174/4885 |
| US-20210188842-A1 | AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | MMP1, ALPI, TIMP3 | TYK2 2940/4885JAK1 1001/4885JAK2 1480/4885 |
| US-11203595-B2 | Aza-indazole compounds for use in tendon and/or ligament injuries | MMP1, ALPI, TIMP3 | TYK2 2940/4885JAK1 1001/4885JAK2 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.